// App-Quantinova.ai

2052 : Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.

Researchers

Presenter

  • Francois M. Lebel

Principal Investigators

  • John A. Barrett

  • E. Antonio Chiocca

  • John Yu

  • Rimas Vincas Lukas

  • Seema Nagpal

  • Priya Kumthekar

  • Suma Krishnan

  • Laurence JN Cooper

Medical Centers

  • ZIOPHARM Oncology, Boston, MA

  • ZIOPHARM Oncology, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • The University of Chicago Medical Center, Chicago, IL

  • Stanford University Cancer Institute, Stanford, CA

  • Northwestern Memorial Hospital, Chicago, IL

  • Intrexon Corporation, Germantown, MD

Locations

  • United States

Companies

  • Ziopharm Oncology, I

  • Intrexon Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Ad-RTS-hIL-12

Outcome

  • N/A

Study Design

  • Multicenteric

  • Controlled

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02026271

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved